1Vollmer RT, Egawa S, Kuwao S, et al. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men [J]. Cancer, 2002, 94(6): 1692-1698.
2Svatek RS, Shulman M, Choudhary PK, et al. Critical analysis of prostate-specific antigen doubling time calculation methodology [J]. Cancer, 2006, 106(5):1047-1053.
3Roberts SG, Blute ML, Bergstralh El, et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer[J]. Mayo Clin Proc, 2001, 76(6) :576-581.
4Ross PL, Mahmud S, Stephenson AJ, et al. Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations [J]. Urology, 2004, 64(2) :323-328.
5McLaren DB, McKenzie M, Duncan G, et al. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma[J]. Cancer, 1998, 82(2):342-348.
6Stephenson AJ, Aprikian AG, Souhami L, et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer [J]. Urology, 2002, 59(5):652-656.
7Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer [J]. Eur Urol, 2005, 47(1):16-21.
8Kakehi Y. Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era[J]. Jpn J Clin Oncol, 2003, 33 (1):1-5.
9Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen [J]. J Urol, 1997, 158(4):1441-1445.
10Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy [J]. JAMA 1999, 281( 17):1591-1597.
